Mylan Didn't Infringe Invalid Mirapex Patent: Judge

Law360, New York (May 13, 2009, 12:00 AM EDT) -- Boehringer Ingelheim Pharmaceuticals Inc. on Wednesday lost its bid to hold Mylan Pharmaceuticals Inc. accountable for allegedly infringing its patent covering restless leg syndrome treatment Mirapex after a federal judge agreed with Mylan that Boehringer's patent had already been declared invalid by a separate court.

In a ruling in the U.S. District Court for the District of New Jersey, Judge Faith S. Hochberg granted Mylan's motion to dismiss Boehringer's infringement case related to the patent, which was held invalid by the U.S. District Court for the...
To view the full article, register now.